NASDAQ:ERNA Eterna Therapeutics (ERNA) Stock Price, News & Analysis → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free ERNA Stock Alerts $1.91 -0.15 (-7.28%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$1.83▼$2.1950-Day Range$1.74▼$2.4452-Week Range$0.84▼$2.99Volume11,652 shsAverage Volume9,290 shsMarket Capitalization$10.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Eterna Therapeutics alerts: Email Address Ad Chaikin AnalyticsLog Into Marc's $5,000 System TodayNew Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. About Eterna Therapeutics Stock (NASDAQ:ERNA)Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More ERNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERNA Stock News HeadlinesMay 23, 2024 | americanbankingnews.comEterna Therapeutics (NASDAQ:ERNA) Stock Price Down 5.4%May 10, 2024 | globenewswire.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 8, 2024 | globenewswire.comEterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardMay 7, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 7, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusMarch 27, 2024 | finance.yahoo.comQ4 2023 Cognition Therapeutics Inc Earnings CallMarch 26, 2024 | msn.comViking Therapeutics' experimental tablet helps reduce weight in small studyMarch 15, 2024 | investorplace.comERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023February 23, 2024 | benzinga.comEterna Therapeutics Stock (NASDAQ:ERNA) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsFebruary 20, 2024 | globenewswire.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsJanuary 12, 2024 | msn.comEterna Therapeutics files to sell 18.2M shares for holdersJanuary 3, 2024 | finance.yahoo.comEterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)December 21, 2023 | finance.yahoo.comEterna Therapeutics Appoints Sanjeev Luther as President and CEODecember 20, 2023 | msn.comEterna Therapeutics names Sanjeev Luther as CEODecember 20, 2023 | finance.yahoo.comEterna Therapeutics Names Sanjeev Luther as President and Chief Executive OfficerDecember 15, 2023 | msn.comEterna Therapeutics launches convertible debt and warrant financing of up to $9.2MDecember 14, 2023 | finance.yahoo.comEterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingDecember 6, 2023 | markets.businessinsider.comTreadwell Announces Strategic Pipeline Prioritization and Leadership TransitionsNovember 1, 2023 | finance.yahoo.comEterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of DirectorsOctober 30, 2023 | markets.businessinsider.comCalidi Biotherapeutics Names Andrew Jackson CFOOctober 30, 2023 | marketwatch.comCalidi Biotherapeutics Names Andrew Jackson Chief Financial OfficerOctober 5, 2023 | markets.businessinsider.comPositive Clinical Outcomes and Continued Genentech Support Bolster Buy Rating for Lineage Cell Therapeutics: An Analysis of OpRegen’s PotentialSeptember 13, 2023 | uk.finance.yahoo.comStem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033: VisiongainSeptember 8, 2023 | finance.yahoo.comInsider Stock Buying Reaches US$2.7m On Eterna TherapeuticsSee More Headlines Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/28/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ERNA CUSIPN/A CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,670,000.00 Net MarginsN/A Pretax Margin-19,915.65% Return on Equity-1,466.71% Return on Assets-46.26% Debt Debt-to-Equity Ratio3.03 Current Ratio0.79 Quick Ratio0.79 Sales & Book Value Annual Sales$70,000.00 Price / Sales147.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book4.66Miscellaneous Outstanding Shares5,410,000Free Float3,493,000Market Cap$10.33 million OptionableNo Data Beta4.31 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Sandra M. Gurrola (Age 57)Principal Financial & Accounting Officer and Senior VP of Finance Comp: $305.88kMr. Sanjeev Luther (Age 62)CEO, President & Director Ms. Dorothy J. Clarke (Age 58)General Counsel & Director Key CompetitorsDaré BioscienceNASDAQ:DAREGain TherapeuticsNASDAQ:GANXNextCureNASDAQ:NXTCReviva PharmaceuticalsNASDAQ:RVPHNRx PharmaceuticalsNASDAQ:NRXPView All CompetitorsInstitutional OwnershipAvidian Wealth Solutions LLCBought 14,798 shares on 5/3/2024Ownership: 0.274%Sippican Capital AdvisorsBought 18,750 shares on 5/2/2024Ownership: 1.346%View All Institutional Transactions ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed in 2024? Eterna Therapeutics' stock was trading at $1.7950 at the start of the year. Since then, ERNA stock has increased by 6.4% and is now trading at $1.91. View the best growth stocks for 2024 here. Are investors shorting Eterna Therapeutics? Eterna Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 52,800 shares, an increase of 54.4% from the April 30th total of 34,200 shares. Based on an average trading volume of 9,500 shares, the days-to-cover ratio is presently 5.6 days. Currently, 1.9% of the company's shares are short sold. View Eterna Therapeutics' Short Interest. When is Eterna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our ERNA earnings forecast. How were Eterna Therapeutics' earnings last quarter? Eterna Therapeutics Inc. (NASDAQ:ERNA) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($1.14) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million for the quarter. Who are Eterna Therapeutics' major shareholders? Eterna Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sippican Capital Advisors (1.35%) and Avidian Wealth Solutions LLC (0.27%). Insiders that own company stock include John D Halpern and Nicholas Jason Singer. View institutional ownership trends. How do I buy shares of Eterna Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ERNA) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
